Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Update on new agents in multiple myeloma – focus on monoclonal antibodies: an expert roundtable discussion

Published: 19 Apr 2016

Views: 1126

Rating:

Save

Michel Delforge, Hermann Einsele, Philippe Moreau and Niels van de Donk

Watch ecancer's expert panel debate the new agents in multiple myeloma with a focus on monoclonal antibodies

Live on the 14th of April at 17:00-18:00 CEST.

Michel Delforge (Belgium), Hermann Einsele (Germany), Philippe Moreau (France) and Niels van de Donk (Netherlands) review updates on new agents in multiple myeloma – focusing on monoclonal antibodies.

After viewing this broadcast you should be able to summarise key clinical data and practical management approaches with monoclonal antibodies in multiple myeloma and discuss the rationale for their use in multiple myeloma therapy.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related Videos

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey

Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

More from ecancer